Cardiff Oncology, Inc. Common Stock vs. Repligen Corp
Cardiff Oncology, Inc. Common Stock and Repligen Corp are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CRDF | RGEN | |
|---|---|---|
| Market Cap | $74.71 million | $9.00 billion |
| Revenue (TTM) | — | $785.10 million |
| Net Income (TTM) | — | $41.54 million |
RGEN leads on 1 of 1 size & scale factors.
Valuation
| CRDF | RGEN | |
|---|---|---|
| P/E Ratio | — | 218.41 |
| Price / Book | — | 4.26 |
| Price / Sales | — | 11.46 |
CRDF and RGEN split the valuation factors evenly.
Profitability
| CRDF | RGEN | |
|---|---|---|
| Net Margin | — | 5.29% |
| Return on Equity | — | 1.97% |
CRDF and RGEN split the profitability factors evenly.
Risk & Sentiment
| CRDF | RGEN | |
|---|---|---|
| Short Interest | 1.17% | 7.13% |
CRDF leads on 1 of 1 risk & sentiment factors.
Dig deeper: CRDF overview, CRDF financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.